Mpox in Africa prompts $661m funding from Gavi for vaccines

Sign up now: Get ST's newsletters delivered to your inbox

(FILES) This file photo taken on August 10, 2022 shows a pharmacist administering a dose of Imvanex, a vaccine to protect against Monkeypox virus, at a pharmacy in Lille, northern France. Shares of the pharmaceutical laboratories of Bavarian Nordic in Denmark, which manufactures a specific vaccine against the mpox, jumped up on August 15, 2024 following the decision of the World Organization of Health WHO to consider the resurgence of monkeypox cases together with an urgent need for health care in the world. A surging mpox outbreak in Africa, which was declared an emergency by the continent's health agency on August 13, is being driven by a new, more transmissible strain of the virus. The Africa Centres for Disease Control and Prevention (Africa CDC) declared its first-ever Public Health Emergency of Continental Security (PHECS) for the deadly disease. (Photo by FRANCOIS LO PRESTI / AFP)

Global vaccine group Gavi has up to $660 million to spend on getting shots to countries affected by an mpox outbreak.

PHOTO: AFP

Follow topic:

- Global vaccine group Gavi has up to US$500 million (S$660 million) to spend on getting shots to countries affected by an escalating mpox outbreak in Africa, its chief executive Sania Nishtar told Reuters.

Gavi helps countries with less resources buy and deploy vaccines, usually against childhood vaccines like measles, but it expanded into broader efforts during the Covid-19 pandemic.

The money is available in the organisation’s “First Response” fund, which was set up after global health agencies like Gavi were left behind by high-income countries in procuring vaccines during the early days of Covid-19.

It can be used to

respond to health emergencies,

which were declared by the World Health Organisation and the Africa Centres for Disease Control and Prevention this week.

The funds are left over largely from money donated by governments and global health funders for the Covid-19 response.

“The money for the vaccines is ready to be tapped,” said Dr Nishtar, but there were hurdles to clear, including official requests for vaccines from affected countries, as well as approvals of the vaccines from the World Health Organisation (WHO), which declared mpox a global health emergency on Aug 14.

Gavi and Unicef, which work together to buy vaccines, cannot do so without WHO approving them.

On Aug 14, the global health agency said it was hoping to finalise its evaluation of the vaccines by September.

Dr Nishtar said Gavi was also in early talks with the manufacturers of the two mpox vaccines that are widely used, made by Bavarian Nordic and LM Biologics. Official orders can proceed only after approval, she said.

Bavarian Nordic has said it can make 10 million doses by the end of 2025.

“We have already significant capacity in place and can easily handle delivery of all doses needed for the outbreak,” a Bavarian Nordic spokesman said by e-mail.

"But we need someone to buy the doses. None of the organisations have shown interest so far," he added, without providing details.

KM Biologics said in an e-mail it would cooperate with WHO as much as possible.

In the meantime, Gavi is coordinating with countries like the US, which has had 50,000 doses available for donation for months. Bavarian Nordic has also donated 15,000 doses.

However, the Democratic Republic of Congo, which has been severely impacted by the outbreak, has yet to make an official request for the shots, which Dr Nishtar said was a delaying factor, along with arranging legal processes and deployment plans for vaccination.

In a press conference on Aug 15, Congo’s Health Minister Samuel Roger Kamba Mulamba said the country needs three million vaccine doses.

“That’s why it was important to wake up the international community,” he said. REUTERS

See more on